Purpose of review To review the role of prebiopsy multiparametric MRI in biopsy-naïve men for the detection of clinically significant prostate cancer.
INTRODUCTION
Prostate cancer is the second commonest cancer in men in the world [1] . Prostate-specific antigen (PSA) testing forms the basis for screening men at risk of prostate cancer for further investigation. The benefit of PSA screening has been widely debated as there is a fine margin between offering a survival benefit and inflicting harm from overtreatment [2, 3] . The United States Preventive Services Task Force recommended against prostate cancer screening and gave it a grade D recommendation [4] . There is therefore, a need to optimize diagnostic strategies that identify men with clinically significant cancer who will benefit from treatment.
Advances in prostate MRI tend to suggest that it should have a key role in the prostate cancer management algorithm, particularly before a biopsy is done. Recent studies such as the prostate MRI imaging study (PROMIS) trial raise an important question as to whether prebiopsy multiparametric MRI (mpMRI) should have a routine role in biopsy-naïve men for the identification of prostate cancer [5 urology association guidelines endorse a diagnostic pathway that includes a digital rectal examination (DRE) and PSA typically followed by a 10-12 core transrectal ultrasound (TRUS)-guided prostate biopsy if either of the two is abnormal [6] [7] [8] .
The use of prebiopsy MRI in the routine prostate cancer guidelines appears to be lagging behind adoption of the technology in many centres. The National Comprehensive Cancer Network in their 2016 guidelines state that 'MRI is not recommended routinely prior to initial prostate biopsy'; however, they do acknowledge that MRI-ultrasound fusion targeted biopsy may increase the detection of clinically significant higher risk disease, whereas lowering the detection of lower risk disease [9] . However, to recommend MRI routinely, both diagnostic accuracy and cost-effectiveness should be clearly demonstrated. The UK national institute of healthcare and excellence guidelines on prostate cancer: diagnosis and management will be updated in mid 2017 and it is likely that guidelines on the use of prebiopsy MRI in biopsy-naïve men will be featured especially in light of the recent publication of the PROMIS Trial [5 && ,10].
PROBLEMS WITH THE EXISTING DIAGNOSTIC PATHWAY THAT MRI MAY POTENTIALLY SOLVE
The current screening pathway of DRE, PSA then TRUS biopsy has its limitations. The European randomized screen for prostate trial found that 75.9% of men with a PSA greater than 3.0 ng/ml that went on to have a TRUS biopsy were negative for cancer. They also found a cumulative risk of 12% of at least one false-positive PSA after three rounds of PSA testing every 4 years. The Rotterdam Centre had a rate of overdiagnosis as high as 66% [3] .
The standard systematic 12 core TRUS biopsy has a sensitivity ranging from 45 to75% for clinically significant prostate cancer [11] [12] [13] . Transperineal template mapping biopsy has sought to improve on these sensitivities by taking more cores and sampling the anterior and midline prostate which can be difficult to reach via the transrectal route. It also reduces the risks of sepsis associated with the transrectal route. However, transperineal template mapping biopsy usually requires dedicated equipment, expertise, spinal or general anesthesia and can result in greater overdetection of clinically insignificant cancer [14] .
Adverse events associated with the TRUS biopsy procedure are well documented. Hematuria/hematospermia rates are between 20 and 50%. Fever postbiopsy is between 3.5 and 4.2% [3] . More serious complications were found in 68/100 000 biopsies that is, infections, bleeding, and urinary difficulties [2] . Hospitalization post biopsy was found to be 4% [15] . Of concern was the recent finding that a man with a negative TRUS biopsy had a risk of death from prostate cancer of 5.2%, which is greater than the lifetime risk of prostate cancer death for the average man [16, 17] .
By performing a pre-TRUS biopsy mpMRI it may be possible to:
Reduce the number of biopsies performed, thereby, reducing over diagnosis, false-positive rates and adverse events associated with biopsy. It may also be possible to target suspicious lesions more accurately to improve sensitivity and specificity for the detection of clinically significant cancer [18] .
IMPROVEMENTS IN MRI
When MRI was first considered for prostate cancer diagnosis, it lacked sensitivity and specificity when compared to TRUS biopsy as it was limited to the use of anatomic T2 weighted MRI sequences. The rapid optimization of MRI technology has led to functional imaging using diffusion weighted, dynamic contrast enhanced, and spectroscopic imaging. Combining these functional techniques with the traditional (T1/T2) techniques (parameters) resulted in a mpMRI which has led to improved diagnostic performance for the detection of highgrade lesions [19] .
The European society of urogenital radiology and other expert Uroradiology groups have led attempts at standardizing the reporting of prostate mpMRI [20] . The prostate imaging reporting and data system and Likert scores for ascribing risk of clinically KEY POINTS Level 1 evidence shows that prebiopsy multiparametric MRI has a high sensitivity and negative predictive value for the detection of clinically significant prostate cancer in biopsy-naïve men.
Prostate MRI may be able to be used as a triage test to allow a proportion of men to avoid biopsy and remain on PSA surveillance.
The low specificity and positive predictive value of MRI means that prostate biopsy is still necessary. MRItargeted biopsy appears to be a reasonable alternative to standard 12 core TRUS-guided prostate biopsy though the optimal technique and its exact role in biopsy-naïve men remains to be established.
Analyses showing cost-effectiveness of an MRI-driven diagnostic pathway in biopsy-naïve men are awaited.
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www.co-urology.comsignificant prostate cancer represent significant steps forward in increasing the applicability of the prostate MRI in nonexpert centres [21] . It is clear from the experience of multicentre clinical trials in prostate MRI such as PROMIS and PRostate evaluation for clinically important disease: sampling using imageguidance or not (PRECISION) (NCT02380027), that optimization of the conduct of the MRI and reporting experience of the radiologists are key factors in determining the performance of the technology.
The PROMIS provides level 1 evidence for the contemporary diagnostic performance of mpMRI validated against transperineal template biopsy in biopsy-naïve men [5 && ]. In total, 576 men underwent 1.5T mpMRI with a reference standard of transperineal template biopsy. Sensitivity was 93%, specificity 41%, positive predictive value 51%, and negative predictive value 89% for the detection of clinically significant cancer (Gleason score 4 þ 3 or a maximum cancer core length 6 mm or longer). MpMRI compared favourably to TRUS biopsy with regards to sensitivity and negative predictive value, though the specificity and positive predictive value of TRUS biopsy were superior. The implications of these results will be discussed in the appropriate sections below where the potential role of mpMRI in the diagnostic pathway for prostate cancer will be discussed (Table 1) .
MULTIPARAMETRIC MRI AS A TRIAGE TEST
By doing a pre biopsy mpMRI it may be possible to exclude men at low risk of having clinically significant cancer from going on to having a biopsy. To do this, mpMRI needs to have a high negative predictive value for the detection of clinically significant cancer. The negative predictive value of mpMRI for clinically significant prostate cancer varies widely in the available literature. This may depend on the techniques, interpreters or the definition of clinically significant prostate cancer used. A literature review by Futterer et al. [22 & ] has found a range from 63 to 98%.
The PROMIS trial is one of the largest prospective level 1b evidence trials to add evidence to this debate [5 && ]. Several of the centres involved in PROMIS were not specialized academic centres and MRI was carried out on 1.5T machines rather than 3T to show the performance of the test in scanners with coil strengths that are more readily accessible to most centres. The landmark finding was that of a negative predictive value of 89% for the detection of clinically significant prostate cancer (Gleason score 4 þ 3 or a maximum cancer core length 6 mm or longer). Of note, no patients with dominant Gleason pattern 4 were missed. All misses were Gleason 3 þ 4 with maximum cancer core length 6 mm or greater. The study design ensured the conduct and reporting of MRIs was tightly controlled and this standardization will need to be replicated in other nonspecialist centres if these results wish to be replicated.
However, according to the secondary definition of clinically significant prostate cancer (Gleason score 3 þ 4 or a maximum cancer core length 4 mm) the negative predictive value was 72%. For some practitioners, missing 28% of clinically significant cancer according to this less stringent definition may seem high. One should appreciate, however, that men with negative MRIs are not discharged without follow-up but continue on PSA surveillance. Recent studies have shown that a low PSA density is a useful adjunct to a negative MRI in ruling out a greater proportion of significant cancer. Following a negative MRI, a PSA density of less than 0.15 ng/ml could be used to further inform decisions to avoid a biopsy [23, 24] .
Further, the results must be appreciated in the context of what men would otherwise get. If it was a TRUS biopsy, the negative predictive value was still lower than MRI in this study. At the very least, the results of this trial allow an informed discussion with a man who has a negative MRI to consider whether he wishes to avoid a biopsy and embark on PSA surveillance.
Before routinely adapting prebiopsy MRI in all biopsy-naïve men, this practice would need to be proven cost-effective. Although cost-effectiveness in the prior negative biopsy group has been demonstrated, we await robust cost-effectiveness analysis in the biopsy-naïve group [25] .
MULTI PARAMETRIC MRI AS AN ADDITIONAL TEST TO GUIDE MRI-TARGETED BIOPSY
If a suspicious lesion has been identified on an MRI, this can be sampled by a targeted biopsy. Currently, the three ways to do so are MRI visual estimation/ cognitive registration, MRI-ultrasound fusion, and the In-bore MRI guided biopsy. Cognitive biopsies After digital rectal examination and prostate-specific antigen testing as a triage test to decide on which men can avoid biopsy and which need to go onto biopsy After digital rectal examination and prostate-specific antigen testing as an additional test to guide MRI-targeted biopsy, whether cognition, fusion, or in-bore MRI guided rely on the operator to review the images and make an effort to deliberately sample the suspicious area using TRUS guidance. MRI fusion biopsies use software to coregister the MRI prostate contours and lesion location onto the real time ultrasound. In bore MRI-targeted biopsies are done within an MRI scanner, using MRI compatible biopsy equipment.
There are few original studies in MRI-targeted biopsies that are appropriately powered to be able to tell if there is a difference between clinically significant cancer detection by MRI-targeted biopsy and TRUS biopsy. An ongoing prospective randomized trial, PRECISION (NCT02380027), will attempt to address this, comparing cancer detection rates (CDRs) of MRI-targeted prostate biopsy to TRUS biopsy in 470 biopsy-naïve men. There are, however, many smaller studies already published from specialist centres which have found significant improvements in CDRs, particularly with regards to clinically significant cancer, and lower detection rates of clinically insignificant cancer rates using MRI-guided techniques [26- ]. It has not been established whether one particular technique for MRI-targeted biopsy is superior to another. The PROFUS trial, a prospective blinded comparison of the CDRs of MRI-targeted cognition TRUS biopsy and MRI-TRUS fusion showed no statistically significant difference in CDRs between the two types of MRI-targeted biopsy registration techniques however, there was a trend toward improved CDRs in their subgroup analysis. The authors suggest that these results may be because of the fact that there were only 125 patients in the study [33] .
Data from some of the key recent studies in biopsy-naïve men evaluating MRI-targeted biopsy are summarized in ]. This study highlights one of the key advantages of the MRI-influenced pathway: the ability to identify significant cancer, whereas avoiding the diagnosis of clinically insignificant cancer.
Another important consideration is whether an MRI-targeted only biopsy approach (i.e. no additional systematic cores) can be taken or whether additional systematic cores need to be taken from MRI-negative areas. Baco et al. performed a randomized control trial on 175 biopsynaïve men comparing a standard TRUS biopsy and 2 core TRUS targeted biopsy of DRE or TRUS suspicious lesion versus a 2-core MRI-TRUS fusion biopsy and standard TRUS biopsy [35] . They found no significant difference in overall cancer detection rates (54 versus 59%; P value 0.4) or clinically significant prostate cancer detection rates (49 versus 44%; P value 0.5) between the two groups. Interestingly, they found no statistically significant difference in the clinically significant CDR between a 2 core MRI/TRUS fusion biopsy versus standard biopsy (38 versus 49%; P value 0.2). This tends to suggest a targeted two core approach may be sufficient [35] .
Urologists should carefully consider the balance between biopsy core number, clinically significant and clinically insignificant disease detection and not always assume taking more biopsies is the best strategy. We should consider that we are in a resource-limited environment and an MRI targeted only approach, which would result in fewer biopsies and fewer men diagnosed with insignificant cancer will have health economic and service delivery advantages.
Though equipment for fusion and in-bore MRI techniques may be costly, this may be balanced out by costs saved if fewer men are biopsied and fewer biopsy cores per patient are taken. Issues on www.co-urology.com training nonspecialist centres must also be considered [36] .
CONCLUSION
There have been recent notable developments in mpMRI technology, conduct and reporting to improve the use of MRI in prostate cancer management. These have resulted in clear improvements in the performance of prebiopsy mpMRI. Level 1b evidence is now available demonstrating good performance of mpMRI in biopsy-naïve men in ruling out high-grade prostate cancer and support the possibility of its use as a triage test for deciding which men may be able to avoid a biopsy. Some evidence also exists supporting the role of mpMRI-targeted biopsy as an adjunct or replacement test to TRUS biopsy, though questions remain on training and implementation practicalities. We also await robust costeffectiveness data to support routine use of a prebiopsy MRI-influenced diagnostic pathway. What is certain is that prebiopsy mpMRI will play an increasingly important role in biopsy-naïve men in years to come. 
